Biotech Updates: Corporate Subscriptions Now Available

In an industry defined by rapid innovation and complex regulatory landscapes, data is not just information—it is strategic leverage. The newly released ISAAA Brief 57: Global Status of Commercialized Biotech/GM Crops in 2024 provides the definitive roadmap of the global agri-biotech sector. Backed by 29 years of longitudinal data, this report is the industry standard for organizations that need to anticipate market shifts and regulatory trends.

A corporate subscription equips your entire team with the insights necessary to drive growth:

• Trace the 29-year trajectory of biotech adoption to identify emerging markets and high-growth regions.
• Gain a comprehensive view of the research pipeline, identifying the next generation of biotech traits before they hit the commercial market.
• Utilize expert strategic recommendations designed to help stakeholders navigate approval hurdles and accelerate time-to-market.

Select the Subscription Plan that fits your reach: Small Team (up to 20 users) for focused groups, Corporate (21 to 50 users) for growing enterprises, or Institutional for unlimited, organization-wide access.

For inquiries, send an email to knowledge.center@isaaa.org.